RedHill Biopharma Reports the Submission of CTA for P-II/III Study Evaluating Opaganib Against COVID-19 in Russia

 RedHill Biopharma Reports the Submission of CTA for P-II/III Study Evaluating Opaganib Against COVID-19 in Russia

RedHill Biopharma Reports the Submission of CTA for P-II/III Study Evaluating Opaganib Against COVID-19 in Russia

Shots:

  • RedHill has submitted CTA with the Ministry of Health of the Russian Federation for a P-II/III clinical study evaluating Yeliva (opaganib, ABC294640)1 in patients hospitalized with severe COVID-19 and pneumonia
  • The P-II/III study will assess opaganib vs placebo, on top of SOC and plans to enroll 270 patients with severe COVID-19 pneumonia requiring hospitalization and treatment with supplemental oxygenation. The 1EPs of study will be the proportion of patients requiring intubation and mechanical ventilation by day 14
  • An interim analysis will be conducted when ~100 patients have been evaluated for 1EPs. The study will be conducted in clinical sites across Russia and other EU countries. Additionally, RedHill is initiating P-IIa study with opaganib in the US

Click here to read full press release/ article | Ref: Buinesswire | Image: RedHill

Related News: RedHill Biopharma Collaborates with NIAID to Investigate RHB-107 (upamostat, WX-671) Against COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post